1.05
Boundless Bio Inc (BOLD) 最新ニュース
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Boundless Bio Showcases Revolutionary ecDNA Cancer Treatment at Major Goldman Sachs Healthcare Conference - Stock Titan
H.C. Wainwright initiates Boundless Bio stock with buy rating - Investing.com
HC Wainwright & Co. Initiates Coverage of Boundless Bio (BOLD) with Buy Recommendation - Nasdaq
H.C. Wainwright initiates Boundless Bio stock with buy rating By Investing.com - Investing.com India
Boundless Bio initiated with a Buy at H.C. Wainwright - TipRanks
Boundless Bio Inc. Reports Q1 2025 Financial Results - TipRanks
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
Leerink cuts Boundless Bio stock rating on program setback By Investing.com - Investing.com Nigeria
Leerink cuts Boundless Bio stock rating on program setback - Investing.com
Leerink Partners Downgrades Boundless Bio to Market Perform From Outperform, Adjusts PT to $3 From $15 - marketscreener.com
Hold Rating Issued for Boundless Bio Inc. Amid Strategic Setbacks and Delayed Program Validations - TipRanks
Boundless Bio downgraded to Market Perform from Outperform at Leerink - TipRanks
Liposarcoma Clinical Trial Analysis: Key Insights into Rich - GlobeNewswire
Boundless Bio changes plans for cancer drug after toxicity issues - Endpoints News
Boundless Bio To Reduce Its Workforce By About One-third - Nasdaq
Boundless Bio Announces Portfolio Prioritization And Runway Extension - marketscreener.com
Boundless Bio Announces Major Workforce Reduction Strategy - TipRanks
Boundless Bio's Portfolio Adjustments and Streamlined Operations Boost Cash Runway - marketscreener.com
Boundless Bio discontinuing BBI-355 and BBI-825 programs - TipRanks
Boundless Bio Announces Portfolio Prioritization and Extended Operating Runway Through 2028 with Focus on Novel Combination Therapy and New Development Candidate - Nasdaq
Boundless Bio Announces Portfolio Prioritization and Runway Extension - The Manila Times
Silvercrest Asset Management Group Inc. Announces $25 Million Common Stock Repurchase Program - The Manila Times
Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability - Endpoints News
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know - MSN
Boundless Bio reports R&D pipeline progress - The Pharma Letter
Boundless Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
Boundless Bio Reports Q1 2025 Financial Results and Progress on BBI-355 Phase 1/2 Trial and Kinesin Program Development - Nasdaq
New Strong Sell Stocks for May 1st - The Globe and Mail
Boundless Bio’s 2024 Financial Results and Strategic Progress - MSN
Boundless Bio stock plunges to 52-week low of $1.41 - Investing.com Australia
Boundless Bio to Participate in the Needham Virtual Healthcare Conference - TradingView
Boundless Bio stock plunges to 52-week low of $1.41 By Investing.com - Investing.com UK
Boundless Bio plans $14.5M stock sale via Jefferies By Investing.com - Investing.com Australia
Boundless Bio plans $14.5M stock sale via Jefferies - Investing.com India
Boundless Bio Inc Files For Mixed Shelf Of Up To $400 MillionSEC Filing - MarketScreener
Boundless Bio Inc. (BOLD) reports earnings - Quartz
大文字化:
|
ボリューム (24 時間):